Cerebrolysin is a porcine brain-derived peptide hydrolysate, standardized by Ever Pharma through controlled enzymatic hydrolysis of lipid-free porcine brain proteins. Mass spectrometry has identified more than 638 unique peptides, with roughly 85 percent free amino acids and about 15 percent biologically active peptide fractions. It is not FDA approved in the United States and is investigational only here, though it is approved in over 40 countries, including Austria, Germany, Russia, China, and South Korea, for acute ischemic stroke, dementia, and traumatic brain injury.

A central concept Dr. Seeds emphasizes is that the preparation contains no intact growth factor fragments. There are no detectable intact nerve growth factor, BDNF, glial-derived, or ciliary neurotrophic factor fragments. Instead, the mixture exerts neurotrophic-like activity collectively. He frames it as an orchestra of peptides working together, not a single isolated factor, which is why generic alternatives may not reproduce the same biological activity.

Mechanisms reported in preclinical work

The proposed mechanisms span several pathways, most documented in animal or in vitro models:

• Neurotrophic signaling: shifts the pro-NGF to NGF balance toward more mature, biologically active NGF, with effects on TrkA and p75NTR receptors and cholinergic neurotransmission.
• Anti-apoptotic protection: upregulation of BCL2, downregulation of Bax, and reduced caspase-3.
• Anti-inflammatory activity: downregulation of toll-like receptors 2 and 4 and reduced microglial activation in TBI models.
• Synaptic plasticity: enhanced LRRTM4 synaptogenic protein in hippocampal synapses, linked to learning and memory.
• Antioxidant capacity: upregulated superoxide dismutase and glutathione peroxidase, with the Nrf2 pathway still unconfirmed.

Clinical evidence and its limits

The clinical picture is mixed. The CASTA stroke trial showed neutral primary endpoints, with a post hoc severe-stroke subgroup trending toward benefit and lower mortality. Alzheimer’s studies reported cognitive benefit at IV doses, and human biomarker work showed reductions in extracellular-vesicle total tau. The CAPTAIN series suggested improvement in moderate to severe TBI. Dr. Seeds also notes a 2025 retraction of a tau model and Cochrane concerns about industry bias, since most multicenter studies were funded by Ever Pharma. No phase one pharmacokinetic or pharmacodynamic studies exist, and there are no head-to-head comparisons against modern standards such as thrombectomy or anti-amyloid antibodies.

Reported use is IV infusion only, diluted in 100 mL of normal saline over 60 to 90 minutes. Doses in the literature range from 10 to 50 mL depending on indication, with most prescribed dosing around 10 mL.

Key clinical points

• Cerebrolysin is a standardized porcine peptide mixture; its activity arises from the combined fractions, not any single growth factor.
• International approvals cover acute ischemic stroke, dementia, and TBI; it remains investigational in the United States.
• Mechanistic evidence for neurotrophic, anti-apoptotic, anti-inflammatory, and synaptic effects is largely preclinical, with some human biomarker support.
• Clinical results are discordant, no phase one PK/PD data exist, and industry funding raises bias questions.
• Caution is warranted with seizure disorders, renal impairment, porcine allergy, and pregnancy; monitor vitals, renal function, and EEG where seizure history is present.